{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:30:26Z","timestamp":1777613426067,"version":"3.51.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis affects approximately 2% of the global population, with plaque psoriasis being its most prevalent manifestation. Management strategies range from topical therapies for mild cases to systemic interventions for moderate to severe cases. Those include immunosuppressive drugs and biological agents, which are novel therapeutic options that have revolutionized psoriasis management. Patients with psoriasis have a higher risk of developing other autoinflammatory diseases, as well as cancer. In addition, both classic immunosuppressive agents and biologics carry a risk of malignancies. We present a case of a 36-year-old male with a long history of plaque psoriasis and psoriatic arthritis. He was undergoing treatment with secukinumab and also had a history of therapy with infliximab. During the treatment course, the patient noted a progressively enlarging pigmented lesion on his left calf, which was subsequently diagnosed as superficial spreading melanoma. Following this diagnosis, he was informed about the potential oncological risks associated with biological therapy and switched to acitretin and methotrexate. Over two years later, he was diagnosed with ulcerative colitis (UC) after endoscopic evaluation. No melanoma recurrence has been observed to date. Our case report demonstrates the difficulties in managing malignancies in patients receiving biologic therapy, highlighting the necessity for careful medical assessment and examination of patients receiving those types of drugs. In cases of cancer coexistence, a multidisciplinary approach is crucial for the sufficient treatment of both oncological and autoinflammatory diseases. Additionally, medical professionals should be aware of the increased risk of developing other autoinflammatory conditions in individuals with psoriasis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1651517","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:55Z","timestamp":1756181635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Misfortunes never come alone: melanoma and ulcerative colitis after biologic therapy in a psoriatic patient \u2013 a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Aleksandra Wiktoria","family":"Bratborska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Ja\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Bowszyc-Dmochowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142 J.","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Adamska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e028116","DOI":"10.1136\/bmjopen-2018-028116","article-title":"Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort","volume":"9","author":"Egeberg","year":"2019","journal-title":"BMJ Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3390\/jcm12041675","article-title":"Risankizumab therapy for moderate-to-severe psoriasis-A multi-center, long-term, real-life study from Poland","volume":"12","author":"Adamczyk","year":"2023","journal-title":"J Clin Med"},{"key":"B5","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can Fam Physician"},{"key":"B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e14433","DOI":"10.1111\/dth.14433","article-title":"Clinical context for cancer risk of immunosuppressive agents used in dermatology","volume":"34","author":"Daugherty","year":"2021","journal-title":"Dermatol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.3390\/ijms21238984","article-title":"Overcoming immune evasion in melanoma","volume":"21","author":"Eddy","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000838","article-title":"Melanoma risk during immunomodulating treatment","volume":"32","author":"Zheng","year":"2022","journal-title":"Melanoma Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: A systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16245","article-title":"Psoriasis and risk of Malignant lymphoma: a population-based cohort study","volume":"178","author":"Kamstrup","year":"2018","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: should we be paying more attention","volume":"16","author":"Loft","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12164","article-title":"Alcohol consumption and psoriasis: a systematic literature review","volume":"27","author":"Brenaut","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12670","article-title":"Psoriasis and smoking: a systematic review and meta-analysis","volume":"170","author":"Armstrong","year":"2014","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/molecules28114413","article-title":"Chronic inflammation\u2019s transformation to cancer: A nanotherapeutic paradigm","volume":"28","author":"Sohrab","year":"2023","journal-title":"Molecules"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.94849","article-title":"Erythrodermic psoriasis","volume":"37","author":"S\u0142omiak-W\u0105sik","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02172-7","article-title":"Use of methotrexate and risk of skin cancer: a nationwide case-control study","volume":"128","author":"Polesie","year":"2023","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3337","article-title":"Association between low-dose methotrexate exposure and melanoma: A systematic review and meta-analysis","volume":"158","author":"Yan","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.024","article-title":"Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies","volume":"56","author":"Fulchiero","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.3390\/cancers15215181","article-title":"Infliximab for treatment of immune adverse events and its impact on tumor response","volume":"15","author":"Parvathareddy","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and Malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cgh.2023.07.027","article-title":"Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: an updated systematic review and meta-analysis","volume":"22","author":"Gupta","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/jcm14020478","article-title":"Secukinumab for treatment of plaque psoriasis in real-world clinical practice in Spain: A literature review","volume":"14","author":"Daud\u00e9n","year":"2025","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in patients with psoriasis and a personal history of Malignancy: A multicenter real-life observational study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20136","article-title":"The risk of Malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01306-2","article-title":"Safety of interleukin inhibitors in patients with plaque psoriasis and neoplasm: A retrospective study from two referral centers","volume":"43","author":"Gargiulo","year":"2023","journal-title":"Clin Drug Investig"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: A systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease: A systematic review and meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.07.029","article-title":"Incidence and risk of inflammatory bowel disease in patients with psoriasis-A nationwide 20-year cohort study","volume":"139","author":"Egeberg","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3682","article-title":"Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: A bidirectional 2-sample mendelian randomization study","volume":"158","author":"Freuer","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others","volume":"53","author":"Puig","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA","volume":"61","author":"O\u2019Toole","year":"2016","journal-title":"Dig Dis Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1740204","article-title":"Safety update of etanercept treatment for moderate to severe plaque psoriasis","volume":"19","author":"Campanati","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13\u2013222 patients within the UK IBD bioresource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1836313","article-title":"Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review","volume":"33","author":"Conforti","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3391","article-title":"Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis","volume":"29","author":"Uchida","year":"2019","journal-title":"Eur J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1651517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:56Z","timestamp":1756181636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1651517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1651517"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1651517","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1651517"}}